Atezolizumab Immunotherapy Receives FDA Approval for First-Line Treatment of Lung Cancer with High PD-L1 Levels

On 18 May 2020, the US Food and Drug Administration (FDA) approved the following drug for adults whose tumors have high PD-L1 levels and who have metastatic (stage 4) non-small cell lung cancer (NSCLC), for first-line treatment: atezolizumab (Tecentriq). Conditions of use require PD-L1 to stain ≥ % 50 of tumor cells [TC ≥ 50%], or tumor-infiltrating immune-system cells in ≥ % 10 of the tumor area must stain for PD-L1 [IC ≥ 10%], and there must be no EGFR or ALK genetic alterations.
At the same time, the FDA also approved the VENTANA PD-L1 (SP142) Assay as a companion diagnostic device to select patients with NSCLC for atezolizumab treatment.
The IMpower110 Study
The efficacy of atezolizumab was evaluated in IMpower110, a multicenter, international, randomized, open-label trial in patients with stage 4 NSCLC whose tumors were PD-L1-positive (TC ≥ % 1 or IC ≥ % 1). Until disease progression or unacceptable side effects, patients received either 1200 mg of atezolizumab every 3 weeks or platinum-based chemotherapy, with patients randomized 1:1 between the two arms. The primary efficacy outcome was overall survival.
Results

- A statistically significant improvement in overall survival was found among patients with high tumor PD-L1 levels who received atezolizumab compared with those treated with platinum-based chemotherapy.
- Median overall survival was 20.2 months in the atezolizumab arm and 13.1 months in the chemotherapy arm.
- Starting atezolizumab as the initial treatment in this patient group was found to reduce the risk of death by 41% compared with chemotherapy.
- There was no significant difference in overall survival at interim or final analyses for the other two PD-L1 subgroups (TC ≥ % 5 or IC ≥ % 5; and TC ≥ % 1 or IC ≥ % 1).
- Median progression-free survival (PFS) was 8.1 months in the atezolizumab arm and 5 months in the platinum-based chemotherapy arm.
- The overall response rate was 38% with immunotherapy and 29% with chemotherapy.
The most common (> % 20) adverse event with single-agent atezolizumab in IMpower110 was fatigue/asthenia.
The recommended atezolizumab dose for NSCLC is 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks, administered as an intravenous infusion over 60 minutes.
*
Sources
fda.gov - 18 May 2020
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.